LLY
749.85
+1.61%↑
JNJ
177.08
-0.6%↓
ABBV
210.45
+0.22%↑
UNH
348.61
+8.84%↑
AZN
81.26
-0.34%↓
LLY
749.85
+1.61%↑
JNJ
177.08
-0.6%↓
ABBV
210.45
+0.22%↑
UNH
348.61
+8.84%↑
AZN
81.26
-0.34%↓
LLY
749.85
+1.61%↑
JNJ
177.08
-0.6%↓
ABBV
210.45
+0.22%↑
UNH
348.61
+8.84%↑
AZN
81.26
-0.34%↓
LLY
749.85
+1.61%↑
JNJ
177.08
-0.6%↓
ABBV
210.45
+0.22%↑
UNH
348.61
+8.84%↑
AZN
81.26
-0.34%↓
LLY
749.85
+1.61%↑
JNJ
177.08
-0.6%↓
ABBV
210.45
+0.22%↑
UNH
348.61
+8.84%↑
AZN
81.26
-0.34%↓
24h
Current
Min
Max
Income | 78M 75M |
---|---|
Sales | 5.5M 26M |
Profit margin | 288.656 |
Employees | 59 |
EBITDA | -73M -71M |
Recommendations | Strong Buy |
---|---|
12 Months Forecast | +188.12% upside |
Next Earnings | 11 Nov 2025 |
---|
Market Cap | -131M 509M |
---|---|
Previous open | 0 |
Previous close | 0 |
Past performance is not a reliable indicator of future results.
27 Feb 2025, 15:29 UTC
Zevra Therapeutics to Sell Priority-Review Voucher for $150 Million
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 24 USD 188.12%
High 29 USD
Low 18 USD
Based on 7 Wall Street analysts offering 12 month price targets forKemPharm Inc - Dist in the last 3 months.
By TipRanks
Strong Buy
7 ratings
7
Buy
0
Hold
0
Sell
Based on 7 analysts giving stock ratings to KemPharm Inc - Dist in the past 3 months.
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$